Merck & Co. to Initiate P-II Study of MK-5890 for Non-Small Cell Lung Cancer

 Merck & Co. to Initiate P-II Study of MK-5890 for Non-Small Cell Lung Cancer

Merck & Co. to Initiates P-II Study of MK-5890 for Non-Small Cell Lung Cancer

Shots:

  • The P-II study will evaluate MK-5890 + Keytruda (pembrolizumab) in patients with sq. and non-sq. NSCLC prior treated with anti-PD-L1 therapy. The study is the part of pembrolizumab umbrella master protocol (MK-3475-U01)
  • In 2014, Merck signed WW license agreement with Aduro to develop & commercialize MK-5890, under which Aduro received $10M as development milestones on the initiation of P-II study of MK-5890
  • Aduro’s MK-5890 is an anti-CD27 agonist, demonstrated a T-cell enhancement in combination with an immune checkpoint inhibitor and showed complete tumor eradication in its preclinical studies

Click here ­to­ read full press release/ article | Ref: Aduro | Image: WHYY

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post